Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 120 articles:
HTML format
Text format



Single Articles


    August 2017
  1. DUROT E, Tomowiak C, Michallet AS, Dupuis J, et al
    Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14881.
    PubMed     Text format     Abstract available


  2. SCHETELIG J, de Wreede LC, Andersen NS, Moreno C, et al
    Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).
    Br J Haematol. 2017;178:521-533.
    PubMed     Text format     Abstract available


  3. STRATI P, Parikh SA, Chaffee KG, Kay NE, et al
    Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.
    Br J Haematol. 2017;178:394-402.
    PubMed     Text format     Abstract available


  4. ZELLER B, Glosli H, Forestier E, Ha SY, et al
    Hyperleucocytosis in paediatric acute myeloid leukaemia - the challenge of white blood cell counts above 200 x 109 /l. The NOPHO experience 1984-2014.
    Br J Haematol. 2017;178:448-456.
    PubMed     Text format     Abstract available


  5. KARLSSON L, Forestier E, Hasle H, Jahnukainen K, et al
    Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia.
    Br J Haematol. 2017;178:592-602.
    PubMed     Text format     Abstract available


  6. MESSINA M, Chiaretti S, Fedullo AL, Piciocchi A, et al
    Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts.
    Br J Haematol. 2017;178:583-587.
    PubMed     Text format     Abstract available


  7. EYRE TA, Schuh A
    An update for Richter syndrome - new directions and developments.
    Br J Haematol. 2017;178:508-520.
    PubMed     Text format     Abstract available


    July 2017
  8. CHEN Y, Pourabdollah M, Chang H
    Acute myeloid leukemia with mutated NPM1 demonstrating multilineage dysplasia and marked thrombocytosis.
    Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14741.
    PubMed     Text format    


  9. THEUNISSEN PMJ, van den Branden A, Van Der Sluijs-Gelling A, De Haas V, et al
    Understanding the reconstitution of the B-cell compartment in bone marrow and blood after treatment for B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2017;178:267-278.
    PubMed     Text format     Abstract available


  10. WILLIAMS J, Heppel NH, Britt-Compton B, Grimstead JW, et al
    Telomere length is an independent prognostic marker in MDS but not in de novo AML.
    Br J Haematol. 2017;178:240-249.
    PubMed     Text format     Abstract available


  11. ARAI Y, Kondo T, Shigematsu A, Tanaka J, et al
    Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults.
    Br J Haematol. 2017;178:106-111.
    PubMed     Text format     Abstract available


  12. MARTINI V, Gattazzo C, Frezzato F, Trimarco V, et al
    Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
    Br J Haematol. 2017;178:81-93.
    PubMed     Text format     Abstract available


  13. THEUNISSEN PMJ, Sedek L, De Haas V, Szczepanski T, et al
    Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.
    Br J Haematol. 2017;178:257-266.
    PubMed     Text format     Abstract available


  14. SOARES M, Saussoy P, Maskens M, Reul H, et al
    Eliminating malignant cells from cryopreserved ovarian tissue is possible in leukaemia patients.
    Br J Haematol. 2017;178:231-239.
    PubMed     Text format     Abstract available


  15. JONES JA, Hillmen P, Coutre S, Tam C, et al
    Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
    Br J Haematol. 2017;178:286-291.
    PubMed     Text format     Abstract available


  16. STRATI P, Parikh SA, Chaffee KG, Achenbach SJ, et al
    CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2017;178:99-105.
    PubMed     Text format     Abstract available


    June 2017
  17. HO G, Jonas BA, Li Q, Brunson A, et al
    Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.
    Br J Haematol. 2017;177:791-799.
    PubMed     Text format     Abstract available


  18. ONIDA F, de Wreede LC, van Biezen A, Eikema DJ, et al
    Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Br J Haematol. 2017;177:759-765.
    PubMed     Text format     Abstract available


  19. LIU CY, Hsieh FS, Chu PY, Tsai WC, et al
    Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition.
    Br J Haematol. 2017;177:726-740.
    PubMed     Text format     Abstract available


  20. KAYASTHA GK, Ranjitkar N, Gurung R, Kc RK, et al
    The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
    Br J Haematol. 2017;177:1000-1007.
    PubMed     Text format     Abstract available


  21. CORREA DE ARAUJO KOURY L, Ganser A, Berliner N, Rego EM, et al
    Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience.
    Br J Haematol. 2017;177:979-983.
    PubMed     Text format     Abstract available


  22. KAYASTHA GK, Ranjitkar N, Gurung R, Kc RK, et al
    Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate): 10 years' experience at Patan Hospital, Nepal.
    Br J Haematol. 2017;177:991-999.
    PubMed     Text format     Abstract available


    May 2017
  23. TAO L, Clarke CA, Rosenberg AS, Advani RH, et al
    Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
    Br J Haematol. 2017 May 25. doi: 10.1111/bjh.14638.
    PubMed     Text format     Abstract available


  24. EPPERLA N, Pham AQ, Burnette BL, Wiseman GA, et al
    Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
    Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14688.
    PubMed     Text format     Abstract available


  25. SCOTT S, Travis D, Whitby L, Bainbridge J, et al
    Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme.
    Br J Haematol. 2017;177:414-422.
    PubMed     Text format     Abstract available


  26. RHEINGOLD SR, Tasian SK, Whitlock JA, Teachey DT, et al
    A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).
    Br J Haematol. 2017;177:467-474.
    PubMed     Text format     Abstract available


  27. THOMPSON PA, Stingo F, Keating MJ, Wierda WG, et al
    Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.
    Br J Haematol. 2017;177:567-577.
    PubMed     Text format     Abstract available


  28. THOMPSON PA, Ravandi F
    How I manage patients with hairy cell leukaemia.
    Br J Haematol. 2017;177:543-556.
    PubMed     Text format     Abstract available


    April 2017
  29. MARTIN P, Chen Z, Cheson BD, Robinson KS, et al
    Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
    Br J Haematol. 2017 Apr 17. doi: 10.1111/bjh.14667.
    PubMed     Text format     Abstract available


  30. BULDINI B, Rizzati F, Masetti R, Fagioli F, et al
    Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.
    Br J Haematol. 2017;177:116-126.
    PubMed     Text format     Abstract available


  31. ORLOWSKI RJ, Porter DL, Frey NV
    The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.
    Br J Haematol. 2017;177:13-26.
    PubMed     Text format     Abstract available


  32. AKAHANE K, Li Z, Etchin J, Berezovskaya A, et al
    Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2017;177:271-282.
    PubMed     Text format     Abstract available


    March 2017
  33. MINAMI M, Arita T, Iwasaki H, Muta T, et al
    Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib.
    Br J Haematol. 2017 Mar 24. doi: 10.1111/bjh.14608.
    PubMed     Text format     Abstract available


  34. TASIAN SK, Hunger SP
    Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.
    Br J Haematol. 2017;176:867-882.
    PubMed     Text format     Abstract available


    February 2017
  35. SAWAS A, Farber CM, Schreeder MT, Khalil MY, et al
    A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
    Br J Haematol. 2017 Feb 21. doi: 10.1111/bjh.14534.
    PubMed     Text format     Abstract available


  36. SHARMAN JP, Farber CM, Mahadevan D, Schreeder MT, et al
    Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
    Br J Haematol. 2017;176:412-420.
    PubMed     Text format     Abstract available


  37. RINGDEN O, Labopin M, Schmid C, Sadeghi B, et al
    Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
    Br J Haematol. 2017;176:431-439.
    PubMed     Text format     Abstract available


  38. WAN H, Cai J, Chen F, Zhu J, et al
    SOX12: a novel potential target for acute myeloid leukaemia.
    Br J Haematol. 2017;176:421-430.
    PubMed     Text format     Abstract available


  39. BERTAINA A, Vinti L, Strocchio L, Gaspari S, et al
    The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
    Br J Haematol. 2017;176:629-636.
    PubMed     Text format     Abstract available


  40. VARGHESE AM, Howard DR, Pocock C, Rawstron AC, et al
    Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
    Br J Haematol. 2017;176:573-582.
    PubMed     Text format     Abstract available


  41. CHANG CK, Zhao YS, Xu F, Guo J, et al
    TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
    Br J Haematol. 2017;176:600-608.
    PubMed     Text format     Abstract available


  42. ROBAK T, Hellmann A, Kloczko J, Loscertales J, et al
    Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
    Br J Haematol. 2017;176:618-628.
    PubMed     Text format     Abstract available


  43. LUBBERT M, Ihorst G, Sander PN, Bogatyreva L, et al
    Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
    Br J Haematol. 2017;176:609-617.
    PubMed     Text format     Abstract available


    January 2017
  44. WANQUET A, Birsen R, Bonnet C, Boubaya M, et al
    Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
    Br J Haematol. 2017;176:37-49.
    PubMed     Text format     Abstract available


  45. BROWN FC, Cifani P, Drill E, He J, et al
    Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.
    Br J Haematol. 2017;176:86-91.
    PubMed     Text format     Abstract available


  46. SEKIYA Y, Xu Y, Muramatsu H, Okuno Y, et al
    Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2017;176:248-257.
    PubMed     Text format     Abstract available


  47. ZEIDAN AM, Smith BD, Carraway HE, Gojo I, et al
    A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.
    Br J Haematol. 2017;176:241-247.
    PubMed     Text format     Abstract available


  48. HASLE H, Kaspers GJ
    Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia - a review.
    Br J Haematol. 2017;176:168-178.
    PubMed     Text format     Abstract available


  49. FRISHMAN-LEVY L, Izraeli S
    Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapy.
    Br J Haematol. 2017;176:157-167.
    PubMed     Text format     Abstract available


    December 2016
  50. LANGE AP, Lima AS, Lucena-Araujo AR, Jacomo RH, et al
    The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia.
    Br J Haematol. 2016 Dec 26. doi: 10.1111/bjh.14490.
    PubMed     Text format    


    July 2016
  51. DANILOV AV, Lewis LD, Lansigan F, Roudaia L, et al
    A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.
    Br J Haematol. 2016 Jul 5. doi: 10.1111/bjh.14171.
    PubMed     Text format    


    June 2016
  52. GAYNON PS, Sun W
    Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia.
    Br J Haematol. 2016;173:950-7.
    PubMed     Text format     Abstract available


  53. WILLIAMS ME, Hong F, Gascoyne RD, Wagner LI, et al
    Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
    Br J Haematol. 2016;173:867-75.
    PubMed     Text format     Abstract available


  54. GIONA F, Moleti ML, De Benedittis D, Santopietro M, et al
    Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience.
    Br J Haematol. 2016;173:749-53.
    PubMed     Text format     Abstract available


  55. ZUNA J, Moericke A, Arens M, Koehler R, et al
    Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2016;173:742-8.
    PubMed     Text format     Abstract available


    May 2016
  56. SOVERINI S, De Benedittis C, Mancini M, Martinelli G, et al
    Present and future of molecular monitoring in chronic myeloid leukaemia.
    Br J Haematol. 2016;173:337-49.
    PubMed     Text format     Abstract available


  57. FERRET Y, Caillault A, Sebda S, Duez M, et al
    Multi-loci diagnosis of acute lymphoblastic leukaemia with high-throughput sequencing and bioinformatics analysis.
    Br J Haematol. 2016;173:413-20.
    PubMed     Text format     Abstract available


    April 2016
  58. VAN DYKE DL, Werner L, Rassenti LZ, Neuberg D, et al
    The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.
    Br J Haematol. 2016;173:105-13.
    PubMed     Text format     Abstract available


  59. DAVIS Z, Forconi F, Parker A, Gardiner A, et al
    The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity.
    Br J Haematol. 2016;173:127-36.
    PubMed     Text format     Abstract available


  60. JAIN P, Kantarjian H, Sasaki K, Jabbour E, et al
    Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
    Br J Haematol. 2016;173:114-26.
    PubMed     Text format     Abstract available


  61. BALLEN KK, Lazarus H
    Cord blood transplant for acute myeloid leukaemia.
    Br J Haematol. 2016;173:25-36.
    PubMed     Text format     Abstract available


  62. JACKSON RK, Irving JA, Veal GJ
    Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.
    Br J Haematol. 2016;173:13-24.
    PubMed     Text format     Abstract available


  63. JIANG X, Zhang L, Zhou D
    Acute promyelocytic leukaemia with promyelocyte count below 20.
    Br J Haematol. 2016;173:11.
    PubMed     Text format    


  64. RIDER TG, Grace RJ, Newman JA
    Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia.
    Br J Haematol. 2016;173:326-7.
    PubMed     Text format    


  65. DANILOV AV
    Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia--response to Rider et al.
    Br J Haematol. 2016;173:327-8.
    PubMed     Text format    


  66. LOPEZ C, Bergmann AK, Paul U, Murga Penas EM, et al
    Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
    Br J Haematol. 2016;173:265-73.
    PubMed     Text format     Abstract available


  67. ABRAHAO R, Keogh RH, Lichtensztajn DY, Marcos-Gragera R, et al
    Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988-2011: a population-based study.
    Br J Haematol. 2016;173:292-302.
    PubMed     Text format     Abstract available


  68. KERSTEN B, Valkering M, Wouters R, van Amerongen R, et al
    CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia.
    Br J Haematol. 2016;173:219-35.
    PubMed     Text format     Abstract available


  69. MELO CP, Campos CB, Rodrigues Jde O, Aguirre-Neto JC, et al
    Long non-coding RNAs: biomarkers for acute leukaemia subtypes.
    Br J Haematol. 2016;173:318-20.
    PubMed     Text format    


  70. MCGEHEE E, Rakheja D, Oliver D, Chen W, et al
    The importance of plasma D-2HG measurement in screening for IDH mutations in acute myeloid leukaemia.
    Br J Haematol. 2016;173:323-6.
    PubMed     Text format    


  71. GLANCY E, Siles R
    Monoclonal B-cell lymphocytosis and hypogammaglobulinaemia.
    Br J Haematol. 2016;173:316-7.
    PubMed     Text format    


    March 2016
  72. TAKAHASHI H, Watanabe T, Kinoshita A, Yuza Y, et al
    High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group.
    Br J Haematol. 2016 Mar 31. doi: 10.1111/bjh.14068.
    PubMed     Text format     Abstract available


  73. BURKHARDT B, Mueller S, Khanam T, Perkins SL, et al
    Current status and future directions of T-lymphoblastic lymphoma in children and adolescents.
    Br J Haematol. 2016 Mar 15. doi: 10.1111/bjh.14017.
    PubMed     Text format     Abstract available


  74. MILES RR, Shah RK, Frazer JK
    Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Br J Haematol. 2016 Mar 11. doi: 10.1111/bjh.14011.
    PubMed     Text format     Abstract available


  75. GUO RJ, Bahmanyar M, Minden MD, Chang H, et al
    CD33, not early precursor T-cell phenotype, is associated with adverse outcome in adult T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2016;172:823-5.
    PubMed     Text format    


  76. VAN DER VELDEN VH, de Launaij D, de Vries JF, de Haas V, et al
    New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2016;172:769-81.
    PubMed     Text format     Abstract available


  77. IRVING JA
    Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.
    Br J Haematol. 2016;172:655-66.
    PubMed     Text format     Abstract available


  78. FERNANDES CM, Hamerschlak N, Kishimoto RK, Ratis CA, et al
    Radiotherapy-related acute myeloid leukaemia with KMT2A amplification.
    Br J Haematol. 2016;172:653.
    PubMed     Text format    


  79. HOFBAUER SW, Krenn PW, Pinomicronn Hofbauer J, Pucher S, et al
    The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells.
    Br J Haematol. 2016;172:815-9.
    PubMed     Text format    


  80. BERQUET L, Valleron W, Grgurevic S, Quelen C, et al
    Small nucleolar RNA expression profiles refine the prognostic impact of IGHV mutational status on treatment-free survival in chronic lymphocytic leukaemia.
    Br J Haematol. 2016;172:819-23.
    PubMed     Text format    


  81. MAIQUES-DIAZ A, Hernando M, Sanchez-Lopez A, Rio-Machin A, et al
    MAPK8-mediated stabilization of SP1 is essential for RUNX1-RUNX1T1 - driven leukaemia.
    Br J Haematol. 2016;172:807-10.
    PubMed     Text format    


  82. BLECKMANN K, Schrappe M
    Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.
    Br J Haematol. 2016;172:855-69.
    PubMed     Text format     Abstract available


  83. MIDDEKE JM, Herold S, Rucker-Braun E, Berdel WE, et al
    TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2016;172:914-22.
    PubMed     Text format     Abstract available


  84. HINAI AA, Valk PJ
    Review: Aberrant EVI1 expression in acute myeloid leukaemia.
    Br J Haematol. 2016;172:870-8.
    PubMed     Text format     Abstract available


  85. MUNOZ-BALLESTER J, Chen-Liang TH, Hurtado AM, Heras I, et al
    Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: kinetics, clinical impact and absence of STAT3 mutations.
    Br J Haematol. 2016;172:937-46.
    PubMed     Text format     Abstract available


  86. IACCARINO L, Ottone T, Divona M, Cicconi L, et al
    Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
    Br J Haematol. 2016;172:909-13.
    PubMed     Text format     Abstract available


  87. LO-COCO F, Cicconi L, Breccia M
    Current standard treatment of adult acute promyelocytic leukaemia.
    Br J Haematol. 2016;172:841-54.
    PubMed     Text format     Abstract available


  88. WANG HY, McMahon C, Ali SM, Young LE, et al
    Novel FNDC3B and MECOM fusion and WT1 L378fs* 7 frameshift mutation in an acute myeloid leukaemia patient with cytomorphological and immunophenotypic features reminiscent of acute promyelocytic leukaemia.
    Br J Haematol. 2016;172:987-90.
    PubMed     Text format    


  89. VIOLA S, Traer E, Huan J, Hornick NI, et al
    Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance.
    Br J Haematol. 2016;172:983-6.
    PubMed     Text format    


    February 2016
  90. CHANG JE, Havighurst T, Kim K, Eickhoff J, et al
    Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
    Br J Haematol. 2016 Feb 23. doi: 10.1111/bjh.13957.
    PubMed     Text format     Abstract available


  91. HOUGH R, Rowntree C, Goulden N, Mitchell C, et al
    Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.
    Br J Haematol. 2016;172:439-51.
    PubMed     Text format     Abstract available


  92. DEL GIUDICE I, Marinelli M, Wang J, Bonina S, et al
    Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments.
    Br J Haematol. 2016;172:371-83.
    PubMed     Text format     Abstract available


  93. NIAVARANI A, Herold T, Reyal Y, Sauerland MC, et al
    A 4-gene expression score associated with high levels of Wilms Tumor-1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia.
    Br J Haematol. 2016;172:401-11.
    PubMed     Text format     Abstract available


  94. KURTOVIC-KOZARIC A, Hasic A, Radich JP, Bijedic V, et al
    The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients.
    Br J Haematol. 2016;172:420-7.
    PubMed     Text format     Abstract available


  95. RAVANDI F, Jorgensen JL, O'Brien SM, Jabbour E, et al
    Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2016;172:392-400.
    PubMed     Text format     Abstract available


  96. DE BRAEKELEER M, Gueganic N, Tous C, Le Bris MJ, et al
    Translocations involving 13q14 without associated deletion in chronic lymphoid leukaemia target DLEU2.
    Br J Haematol. 2016;172:467-9.
    PubMed     Text format    


  97. DICKSON GJ, Bustraan S, Hills RK, Ali A, et al
    The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia.
    Br J Haematol. 2016;172:573-80.
    PubMed     Text format     Abstract available


  98. AL MALKI MM, Song JY
    Strongyloides hyperinfection syndrome following haematopoietic stem cell transplantation.
    Br J Haematol. 2016;172:496.
    PubMed     Text format    


  99. DEVILLIER R, Raffoux E, Rey J, Lengline E, et al
    Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.
    Br J Haematol. 2016;172:628-30.
    PubMed     Text format    


    January 2016
  100. MAWAD R, Becker PS, Hendrie P, Scott B, et al
    Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
    Br J Haematol. 2016;172:238-45.
    PubMed     Text format     Abstract available


  101. ELSE M, Wade R, Oscier D, Catovsky D, et al
    The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.
    Br J Haematol. 2016;172:228-37.
    PubMed     Text format     Abstract available


  102. MACCHIA G, Lonoce A, Venuto S, Macri E, et al
    A rare but recurrent t(8;13)(q24;q14) translocation in B-cell chronic lymphocytic leukaemia causing MYC up-regulation and concomitant loss of PVT1, miR-15/16 and DLEU7.
    Br J Haematol. 2016;172:296-9.
    PubMed     Text format    


  103. BAUMANN T, Delgado J, Santacruz R, Martinez-Trillos A, et al
    CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.
    Br J Haematol. 2016;172:48-55.
    PubMed     Text format     Abstract available


  104. BRUMMENDORF TH, Cortes JE, Khoury HJ, Kantarjian HM, et al
    Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
    Br J Haematol. 2016;172:97-110.
    PubMed     Text format     Abstract available


  105. LOEB KR, Cherian S, Becker PS, Walter RB, et al
    Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid.
    Br J Haematol. 2016;172:134-6.
    PubMed     Text format    


  106. APOLLONIO B, Ramsay AG
    Subclonal heterogeneity in chronic lymphocytic leukaemia: revealing the importance of the lymphoid tumour microenvironment.
    Br J Haematol. 2016;172:7-8.
    PubMed     Text format    


    December 2015
  107. SHIBA N, Ohki K, Kobayashi T, Hara Y, et al
    High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.
    Br J Haematol. 2015 Dec 18. doi: 10.1111/bjh.13869.
    PubMed     Text format     Abstract available


  108. CHIHARA D, Cheah CY, Westin JR, Fayad LE, et al
    Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
    Br J Haematol. 2015 Dec 9. doi: 10.1111/bjh.13796.
    PubMed     Text format     Abstract available


    November 2015
  109. PREBET T, Sun Z, Ketterling RP, Zeidan A, et al
    Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
    Br J Haematol. 2015 Nov 18. doi: 10.1111/bjh.13832.
    PubMed     Text format     Abstract available


  110. BAIN BJ, Ahmad S
    Chronic neutrophilic leukaemia and plasma cell-related neutrophilic leukaemoid reactions.
    Br J Haematol. 2015;171:400-10.
    PubMed     Text format     Abstract available


  111. LOKIREDDY P, Bloxam D, Hodson A, Whalley I, et al
    Extramedullary acute myeloid leukaemia: isolated leukaemic pleural and pericardial effusions without marrow disease.
    Br J Haematol. 2015;171:295.
    PubMed     Text format    


  112. ZHONG H, Chen G, Jukofsky L, Geho D, et al
    MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.
    Br J Haematol. 2015;171:432-5.
    PubMed     Text format    


  113. DINMOHAMED AG, Brink M, Visser O, Sonneveld P, et al
    Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012.
    Br J Haematol. 2015;171:436-9.
    PubMed     Text format    


    October 2015
  114. AWASTHI A, Ayello J, Van de Ven C, Elmacken M, et al
    Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20 rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukae
    Br J Haematol. 2015 Oct 16. doi: 10.1111/bjh.13764.
    PubMed     Text format     Abstract available


  115. WATTS JM, Kishtagari A, Hsu M, Lacouture ME, et al
    Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center.
    Br J Haematol. 2015;171:84-90.
    PubMed     Text format     Abstract available


  116. VAN LAAR M, Kinsey SE, Feltbower RG
    Survival of childhood acute lymphoid leukaemia in Yorkshire by clinical trial era, 1990-2011.
    Br J Haematol. 2015;171:116-9.
    PubMed     Text format     Abstract available


  117. TANAKA Y, Kato M, Hasegawa D, Urayama KY, et al
    Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia.
    Br J Haematol. 2015;171:109-15.
    PubMed     Text format     Abstract available


  118. DI GIACOMO D, La Starza R, Barba G, Pierini V, et al
    4q12 translocations with GSX2 expression identify a CD7(+) acute myeloid leukaemia subset.
    Br J Haematol. 2015;171:141-5.
    PubMed     Text format    


    September 2015
  119. DOCHERTY SM, Reza M, Turner G, Bowles K, et al
    Resolution of Roth spots in chronic myeloid leukaemia after treatment with imatinib.
    Br J Haematol. 2015;170:744.
    PubMed     Text format    


  120. OLSSON L, Ivanov Ofverholm I, Noren-Nystrom U, Zachariadis V, et al
    The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 19
    Br J Haematol. 2015;170:847-58.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: